Each one of us together for patients.

We believe our approach to selecting our sentinel in vivo and ex vivo programs positions us to build a pipeline across a range of indications and to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.

Patients are counting on us to deliver.

Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.

Our company’s unique strengths include our lipid nano-particle delivery system and our determined focus on product development.